LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Aktien・Gossamer Bio Inc

Gossamer Bio Inc

Open

BrancheGesundheitswesen

0.17 -5.56

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.17

Max

0.18

Schlüsselkennzahlen
By Trading Economics
Einkommen	574K -47M
Verkäufe	3.2M 17M
EPS	-0.2
Gewinnspanne	-275.223
Angestellte	161
EBITDA	1.2M -45M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+2560% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	3. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-33M 46M
Vorheriger Eröffnungskurs	5.73
Vorheriger Schlusskurs	0.17

Nachrichtenstimmung

By Acuity

64%

36%

290 / 344 Ranking in Healthcare

Gossamer Bio Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Juni 2026, 23:22 UTC

Ergebnisse

Wichtige Markttreiber

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3. Juni 2026, 23:09 UTC

Heiße Aktien

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3. Juni 2026, 20:51 UTC

Ergebnisse

Costco Reports 15% Sales Growth in May

3. Juni 2026, 20:43 UTC

Ergebnisse

Broadcom 2Q Revenue Climbs on AI Chip Demand

3. Juni 2026, 23:48 UTC

Market Talk

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3. Juni 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. Juni 2026, 23:35 UTC

Market Talk

Oil Futures Fall on Possible Technical Correction -- Market Talk

3. Juni 2026, 23:15 UTC

Market Talk

Ergebnisse

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3. Juni 2026, 22:08 UTC

Heiße Aktien

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3. Juni 2026, 21:54 UTC

Market Talk

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3. Juni 2026, 21:18 UTC

Ergebnisse

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3. Juni 2026, 21:15 UTC

Ergebnisse

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3. Juni 2026, 21:13 UTC

Ergebnisse

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3. Juni 2026, 21:13 UTC

Ergebnisse

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3. Juni 2026, 21:12 UTC

Ergebnisse

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3. Juni 2026, 21:09 UTC

Ergebnisse

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3. Juni 2026, 21:03 UTC

Ergebnisse

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3. Juni 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. Juni 2026, 20:43 UTC

Ergebnisse

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3. Juni 2026, 20:39 UTC

Akquisitionen, Fusionen, Übernahmen

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3. Juni 2026, 20:37 UTC

Akquisitionen, Fusionen, Übernahmen

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3. Juni 2026, 20:35 UTC

Ergebnisse

Broadcom Stock Falls Despite Record Results -- Barrons.com

3. Juni 2026, 20:21 UTC

Akquisitionen, Fusionen, Übernahmen

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3. Juni 2026, 20:17 UTC

Ergebnisse

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3. Juni 2026, 20:17 UTC

Ergebnisse

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3. Juni 2026, 20:15 UTC

Akquisitionen, Fusionen, Übernahmen

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3. Juni 2026, 20:15 UTC

Ergebnisse

Broadcom 2Q Adj EPS $2.44 >AVGO

3. Juni 2026, 20:15 UTC

Ergebnisse

Broadcom 2Q EPS $1.91 >AVGO

3. Juni 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3. Juni 2026, 20:15 UTC

Ergebnisse

Broadcom 2Q Rev $22.19B >AVGO

Peer-Vergleich

Kursveränderung

Gossamer Bio Inc Prognose

Kursziel

By TipRanks

2560% Vorteil

12-Monats-Prognose

Durchschnitt 5.32 USD 2560%

Hoch 15 USD

Tief 0.28 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Gossamer Bio Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

6 ratings

Buy

Halten

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Gossamer Bio Inc – Dist abgegeben haben.

Stimmung

By Acuity

290 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.